| Literature DB >> 32906619 |
Malwina Mularczyk1, Izabela Michalak2, Krzysztof Marycz1,3.
Abstract
Bioactive compounds of natural origin are gaining increasing popularity. High biological activity and bioavailability, beneficial effects on health and safety of use are some of their most desirable features. Low production and processing costs render them even more attractive. Microorganisms have been used in the food, medicinal, cosmetic and energy industries for years. Among them, microalgae have proved to be an invaluable source of beneficial compounds. Haematococcus pluvialis is known as the richest source of natural carotenoid called astaxanthin. In this paper, we focus on the cultivation methods of this green microalga, its chemical composition, extraction of astaxanthin and analysis of its antioxidant, anti-inflammatory, anti-diabetic and anticancer activities. H. pluvialis, as well as astaxanthin can be used not only for the treatment of human and animal diseases, but also as a valuable component of diet and feed.Entities:
Keywords: Haematococcus pluvialis; applications; astaxanthin; microalgae
Mesh:
Substances:
Year: 2020 PMID: 32906619 PMCID: PMC7551667 DOI: 10.3390/md18090459
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Potential applications of (a) Haematococcus pluvialis and (b) astaxanthin, extracted from this microalga (according to the Web of Science, accessed on 3 August, 2020).
Figure 2Haematococcus pluvialis as a source of active compounds and their applications.
Figure 3Cell morphology of Haematococcus pluvialis on (a) green stage (b) red stage (own source).
Comparison of fatty acid compositions (%) of different H. pluvialis strains.
| Fatty Acids | Kim et al., 2015 [ | Lorenz, 1999 [ | Scodelaro Bilbao et al., 2016 [ | Lei et al. 2012 [ |
|---|---|---|---|---|
| C12:0 lauric | N/A | 0.1 | N/A | 0.28 |
| C14:0 myristic | 0.1 | 0.5 | 1.99 | 0.65 |
| C15:0 pentadecanoic acid | 0.1 | N/A | N/A | 0.25 |
| C16:0 palmitic | 13.7 | 29 | 22.9 | 12.7 |
| C16:1 palmitoleic | 0.5 | 0.6 | 0.35 | 0.7 |
| C16:2 | 0.4 | N/A | N/A | N/A |
| C16:3 | 3.5 | N/A | N/A | N/A |
| C16:4 | 3.3 | N/A | N/A | N/A |
| C17:0 margaric | N/A | 0.2 | N/A | 0.23 |
| C17:1 margaroleic | N/A | 1.3 | N/A | 0.0 |
| C18:0 stearic | 0.7 | 2.1 | 1.15 | 4.79 |
| C18:1 oleic | 4.9 | 25.9 | 16.3 | 11.2 |
| C18:2 linoleic | 24.9 | 20.8 | 23.9 | 13.0 |
| C18:3 linolenic | 39.7 | 12.8 | 12.5 | 2.84 |
| C18:4 octadecatetraenoic | 5.8 | 1.4 | N/A | N/A |
| C20:0 arachidic | N/A | 0.6 | N/A | 0.35 |
| C20:1 gadoleic | 0.5 | 0.3 | N/A | 1.3 |
| C20:2 eicosadenoic | N/A | 1.2 | 2.21 | 0.87 |
| C20:3 eicosatrienoic gamma | N/A | 0.5 | N/A | 0.18 |
| C20:4 arachidonic | 0.9 | 1.4 | 1.92 | 1.77 |
| C20:5 eicosapentaenoic | 0.6 | 0.6 | 0.66 | 0.99 |
| C22:0 behenic | N/A | 0.4 | N/A | 0.16 |
| C24:0 lignoceric | 0.3 | 0.2 | 0.33 | 0.4 |
| C24:1 nervonic acid | 0.1 | 0.1 | N/A | 0.14 |
| Σ SFAs | 15 | 33.2 | 25.3 | 19.8 |
| Σ ΜUFAs | 6 | 28.1 | 16.6 | 12.97 |
| Σ PUFAs | 79.1 | 38.7 | 41.2 | 19.65 |
N/A–not available.
Figure 4Antidiabetic mechanisms of astaxanthin.